Keros Therapeutics, Inc. (KROS) is experiencing a rise in its stock price in pre-market trading on December 6, 2024. This movement comes as research analysts at Wedbush have increased their earnings estimates for the company. The updated forecast for Keros' Q1 2025 earnings is now set at ($1.40) per share, an improvement from the previous estimate of ($1.44). Wedbush maintains an "Outperform" rating on the stock with a target price of $84.00. This positive revision in earnings estimates may be contributing to the upward momentum in Keros' stock.
The current price of Keros Therapeutics' stock is $66.00, reflecting a 2.15% increase from the previous close of $64.61. The stock has seen a high of $67.79 and a low of $63.26 in today's trading session.